Cell Therapeutics CEO James Bianco: An Interview With “The Pink Sheet” DAILY
This article was originally published in The Pink Sheet Daily
Executive Summary
Seattle biotech is looking to “build a more integrated portfolio” with offer to purchase Miami-based DOR BioPharma, Bianco says.
You may also be interested in...
Cell Therapeutics Gets In The Groove With Systems Medicine Acquisition
Johnson & Johnson’s Yondelis is in competition with Systems Medicine’s brostallicin to become first minor groove binding agent on the market.
Cell Therapeutics Gets In The Groove With Systems Medicine Acquisition
Johnson & Johnson’s Yondelis is in competition with Systems Medicine’s brostallicin to become first minor groove binding agent on the market.
FDA Extends Review Of orBec For Acute GI Graft-Versus-Host Disease
DOR BioPharma, meanwhile, has launched a Phase II trial of the oral beclomethasone dipropionate product in the prophylactic GVHD setting.